Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland

Clinical and Vaccine Immunology

Volumn 19, Issue 10, 2012, Pages 1703-

  Barkoff, Alex Mikael ^a   Mertsola, Jussi ^b   Guillot, Sophie ^c   Guiso, Nicole ^c   Berbers, Guy ^d   He, Qiushui ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c INSTITUT PASTEUR   (France)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FILAMENTOUS HEMAGGLUTININ; HEMAGGLUTININ; PENTAVAC; PERTACTIN; PERTUSSIS TOXIN; UNCLASSIFIED DRUG;

BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BORDETELLA PERTUSSIS; COUGHING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINLAND; GENOTYPE; HUMAN; INFANT; LETTER; MALE; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; SEROTYPING;

ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; FEMALE; FINLAND; HUMANS; INFANT; MALE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; VIRULENCE FACTORS, BORDETELLA;

EID: 84867260267     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00367-12     Document Type: Letter

References (9)

1. Bouchez V, et al. 2009. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 27:6034-6041.
2. Guiso N. 2009. Bordetella pertussis and pertussis vaccines. Clin. Infect. Dis. 49:1565-1569.
3. He Q, et al. 2003. Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants. J. Infect. Dis. 187:1200-1205. (Pubitemid 36438959)
4. Heikkinen E, et al. 2008. Bordetella pertussis isolates in Finland: serotype and fimbrial expression. BMC Microbiol. 8:162. doi:10.1186/1471-2180-8- 162.
5. Kallonen T, He Q. 2009. Bordetella pertussis strain variation and evolution postvaccination. Expert Rev. Vaccines 8:863-875.
6. Mäkinen J, Viljanen MK, Mertsola J, Arvilommi H, He Q. 2001. Rapid identification of Bordetella pertussis pertactin gene variants using LightCycler real-time polymerase chain reaction combined with melting curve analysis and gel electrophoresis. Emerg. Infect. Dis. 7:952-958.
7. Otsuka N, et al. 2012. Prevalence and genetic characterization of pertactindeficient Bordetlla pertussis in Japan. PLoS One 7:e31985. doi:10.1371/journal.pone.0031985.
8. Stefanelli P, et al. 2009. A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells. New Microbiol. 32:159-166.
9. Zepp F, et al. 2011. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect. Dis. 11:557-570.